Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 71

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 71
---
4 through July 23, 2024 (Predecessor)

The following table is data derived from the
Consolidated Statement of Operations (in thousands) and the discussions that follow are in approximate amounts

|                                     |     |         Non-GAAP Combined |       |   |     |                      |       |
|                                     |     | Successor and Predecessor |       |   |     |          Predecessor |       |
|                                     |     |                   For the 
                    period 
      commencing January 1 |       |   |     |              For the 
               period 
 commencing January 1 |       |
|                                     |     |                   through 
                   July 23 |       |   |     |              through 
              July 23 |       |
|                                     |     |                      2024 |       |   |     |                 2024 |       |
|                                     |     |                 Unaudited |       |   |     |            Unaudited |       |
| Operating expenses                  |     |                           |       |   |     |                      |       |
| Research and development expenses   |     |                           | 1,171 |   |     |                      | 1,162 |
| General and administrative expenses |     |                           | 4,396 |   |     |                      |   257 |
| Operating loss                      |     |                           | 5,567 |   |     |                      | 1,419 |
| Financial expense (income), net     |     |                           |  (155 | ) |     |                      |     2 |
| Net loss and comprehensive loss     |     |                           | 5,412 |   |     |                      | 1,421 |

Research and Development Expenses

Successor’s and Predecessor’s research
and development expenses totaled $1,171 thousand for the period commencing January 1, 2024 through July 23, 2024, representing an increase
of $9 thousand, or 0.8%, compared to Predecessor’s $1,162 thousand for the same period. The research and development expenses comprise
mainly from salaries and related expenses, from share based payment expenses and other expenses. The increase was immaterial.

General and Administrative Expenses

Successor’s and Predecessor’s general
and administrative expenses totaled $4,396 thousand for the period commencing January 1, 2024 through July 23, 2024, representing an
increase of $